zelluna.com Scam Check: 100/100 Trust | ScamMinder

This website appears legitimate based on AI analysis.

https://zelluna.com redirected to https//www.zelluna.com during the time we crawled it. Zelluna Immunotherapy AS is a biopharmaceutical company focused on developing TCR-based immunotherapies for cancer treatment. The company's mission is to eliminate solid cancers by leveraging the immune system through the development of "off-the-shelf" T cell receptor (TCR)-guided natural killer (NK) cell therapies. Zelluna's approach involves combining the broad target range of TCRs with the high potency and allogeneic nature of NK cells to create innovative cell therapy products for patients with solid tumors and high unmet medical needs. The company's technology and pipeline are centered around the development of allogeneic TCR-NK therapies, with a particular focus on targeting solid tumors. Zelluna has made significant strides in this area, including the appointment of key executives and the presentation of groundbreaking research at prominent industry events. Zelluna's website provides detailed information about its technology, pipeline, recent news, and career opportunities. The company emphasizes its commitment to privacy and data protection, outlining its use of cookies and its approach to collecting and safeguarding personal data. Overall, Zelluna Immunotherapy AS appears to be a legitimate biopharmaceutical company with a specific focus on advancing TCR-based immunotherapies for the treatment of solid tumors. Its website provides comprehensive information about its mission, technology, and recent developments, and it maintains a professional online presence through platforms like LinkedIn. However, as with any investment or business decision, it's important for individuals to conduct thorough research and due diligence before engaging with any company, particularly in the biopharmaceutical and healthcare sectors."

• Biopharmaceutical company focused on TCR-based immunotherapies, Mission to eliminate solid cancers through "off-the-shelf" TCR-guided NK cell therapies, Combining TCRs with NK cells for innovative cell therapy products, Technology and pipeline centered on allogeneic TCR-NK therapies for solid tumors, Appointment of key executives and presentation of research at industry events, Detailed information about technology, pipeline, news, and career opportunities on the website, Emphasis on privacy and data protection, including the use of cookies and data collection practices, Professional online presence through platforms like LinkedIn, Recommendation for individuals to conduct thorough research and due diligence before engaging with any biopharmaceutical company